William G. Lowrie Department of Chemical and Biomedical Engineering





You are cordially invited to attend a seminar on Lowrie Lecture I: Nanolayered Particles for Tissue Targeted Therapies & Lowrie Lecture II: Research and Life Matters: Seeking Passion and Sanity in Career

Paula T. Hammond David H. Koch Professor of Engineering Department Head Department of Chemical Engineering Koch Institute of Integrative Cancer Research Massachusetts Institute of Technology

Lecture I: Wednesday, March 20, 11:30 AM 1080 Physics Research Building 191 W Woodruff Ave Reception at 11:00 PRB Lobby

Lecture II: Thursday, March 21, 11:30 AM 130 Koffolt Laboratories CBEC 151 W Woodruff Ave Reception at 11:00 CBEC Lobby

Professor Paula T. Hammond is the David H. Koch Chair Professor of Engineering at the Massachusetts Institute of Technology, and the Head of the Department of Chemical Engineering. She is a member of MIT's Koch Institute for Integrative Cancer Research, the MIT Energy Initiative, and a founding member of the MIT Institute for Soldier Nanotechnology. Her research in nanomedicine encompasses the development of new biomaterials to enable drug delivery from surfaces with spatio-temporal control. She also investigates novel responsive polymer architectures for targeted nanoparticle drug and gene delivery, and has developed self-assembled materials systems for electrochemical energy devices.

Professor Hammond was elected into the National Academy of Engineering in 2017. She was elected into the National Academy of Medicine in 2016, and into the 2013 Class of the American Academy of Arts and Sciences. She is also the recipient of the 2013 AIChE Charles M. A. Stine Award, which is bestowed annually to a leading researcher in recognition of outstanding contributions to the field of materials science and engineering, and the 2014 AIChE Alpha Chi Sigma Award for Chemical Engineering Research. She has designed multilayered nanoparticles to deliver a synergistic combination of siRNA or inhibitors with chemotherapy drugs in a staged manner to tumors, leading to significant decreases in tumor growth and a great lowering of toxicity. Professor Hammond has published over 320 papers, and over 20 patent applications. She is the co-founder and member of the Scientific Advisory Board of Moderna Therapeutics.

Lecture I Flyer

Lecture II Flyer

